Mitsubishi UFJ Trust & Banking Corp Purchases 33,736 Shares of CVS Health Corporation $CVS

Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 758,355 shares of the pharmacy operator’s stock after acquiring an additional 33,736 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.06% of CVS Health worth $57,172,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in CVS. Norges Bank bought a new stake in CVS Health during the second quarter worth $1,358,698,000. Invesco Ltd. raised its holdings in shares of CVS Health by 15.3% during the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after buying an additional 3,118,626 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of CVS Health by 815.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock worth $183,701,000 after buying an additional 2,372,121 shares during the last quarter. Jennison Associates LLC boosted its stake in CVS Health by 111.7% in the second quarter. Jennison Associates LLC now owns 4,014,139 shares of the pharmacy operator’s stock valued at $276,895,000 after buying an additional 2,117,798 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in CVS Health by 1.7% in the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after acquiring an additional 2,063,737 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Truist Financial set a $100.00 price target on shares of CVS Health in a research note on Wednesday, December 10th. Sanford C. Bernstein restated a “market perform” rating and issued a $91.00 target price on shares of CVS Health in a research report on Tuesday, January 6th. Jefferies Financial Group upped their price target on shares of CVS Health from $92.00 to $98.00 in a report on Thursday, October 30th. Barclays raised their price objective on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. upped their target price on CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Nineteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.86.

CVS Health Stock Performance

NYSE CVS opened at $83.02 on Friday. The company has a market capitalization of $105.39 billion, a price-to-earnings ratio of 218.49, a PEG ratio of 0.76 and a beta of 0.48. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. CVS Health Corporation has a twelve month low of $53.28 and a twelve month high of $85.15. The stock has a fifty day simple moving average of $79.05 and a 200 day simple moving average of $74.78.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping the consensus estimate of $1.36 by $0.24. The firm had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd will be given a $0.665 dividend. The ex-dividend date is Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.2%. CVS Health’s payout ratio is 700.00%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is activating pharmacies and advising patients to pick up prescriptions ahead of a major winter storm — shows operational readiness and continuity of care that can limit service disruption and protect short‑term revenue. Read More.
• Positive Sentiment: CVS announced programs aimed at making health insurance “simpler and more affordable,” signaling potential member growth and pricing or mix improvements for its health-insurance businesses. Read More.
• Positive Sentiment: Operational/PBM changes: CVS said it will cut some prior‑authorization requirements and expand rebate‑sharing — moves that could reduce friction for care delivery, improve customer experience and blunt policy/competitive criticisms. Read More.
• Positive Sentiment: Strategic/innovation: CVS is partnering with the University of Maryland on AI and pharmacy workforce development — a long‑term positive for efficiency and talent pipeline in its retail and clinical operations. Read More.
• Positive Sentiment: Market positioning: Reports show heavy buying of CVS call options, indicating some investors are positioned for further upside in the near term. Read More.
• Neutral Sentiment: Legal outcome: A Bloomberg Law piece says CVS and UnitedHealth successfully defended against an antitrust suit over drug costs — a favorable legal development but not necessarily dispositive for broader PBM scrutiny. Read More.
• Negative Sentiment: House Judiciary Committee report accuses CVS/Caremark of thwarting competition and targeting independent pharmacies — the committee alleges anticompetitive PBM practices, escalating regulatory and litigation risk that could pressure margins and valuation. Read More.
• Negative Sentiment: Follow‑up coverage: Multiple outlets (Becker’s, Seeking Alpha, MSN) detail the committee’s findings and show CVS executives were scrutinized in hearings over high costs and PBM conduct — these stories amplify political and regulatory uncertainty that investors price as risk. Read More. Read More. Read More.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.